Phase Ib/IIa Study of VES001 in Asymptomatic Frontotemporal Dementia Patients with Gene Mutations
VES001 Treatment Initiated for Frontotemporal Dementia Dosing of VES001 has begun for patients with genetic mutations linked to frontotemporal dementia (FTD), specifically the GRN type, which is a progressive and fatal neurodegenerative disease. This...
Read More